Business Context and Reporting Period
This Form 8-K Current Report was filed by Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) on January 6, 2026, covering an event that occurred on January 5, 2026. The filing addresses a change in the composition of the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the resignation of James W. Newman, Jr. from the Board of Directors, effective immediately on January 5, 2026. Key details include:
- Mr. Newman served as a non-employee director.
- He was a member of both the Audit Committee and the Compensation Committee.
- The Company stated that Mr. Newman did not advise of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, operational outlook, or new risk factors. Management commentary is limited to the confirmation of the resignation and the absence of any disagreement with the departing director.
Key Facts for Investor Verification
- Verify the immediate impact of Mr. Newman's departure on the quorum and composition of the Audit and Compensation Committees.
- Confirm whether the Company has announced a timeline or process for appointing a replacement director.
- Review subsequent filings to ensure no undisclosed disagreements or related party transactions are associated with the resignation.